Diabetic Peripheral Neuropathy Market

DelveInsight’s ‘Diabetic Peripheral Neuropathy - Market Insights, Epidemiology, and Market Forecast-2030’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Diabetic Peripheral Neuropathy in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Diabetic Peripheral Neuropathy from 2017 to 2030 segmented by seven major markets.


Diabetic peripheral neuropathy (DPN) also known distal symmetric polyneuropathy (DSPN) is defined as the symptoms and/or signs of peripheral nerve dysfunction and nerve damage in diabetic patients after the exclusion of other causes. It is a predominantly sensory neuropathy with autonomic nervous system involvement, although there are often motor features with advancing disease.


The signs and symptoms of DPN include numbness, tingling, poor balance, pain: burning, electric shocks, stabbing, spontaneous pain at the affected site, hypersensitive to pain against nociceptive warmth stimulation, and others.


The clinical manifestations of DPN include painful diabetic neuropathy (pDPN) that is often accompanied by burning pain, aching, shooting, stabbing and paresthesia or allodynia often present in arms, hands, legs, and feet. DPN without painful symptoms is referred to as nonpainful diabetic neuropathy (non-pDPN). Due to the presence of pain, pDPN patients are expected to get diagnosed and expected to incur higher health care costs compared to the general population and non-pDPN.


Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Diabetic Peripheral Neuropathy Disease Understanding and Treatment Algorithm

As per the American Diabetes Association, most common among diabetic neuropathies are chronic DPN, accounting for about 75% of the diabetic neuropathies. It is common prevalent complication in neurological damage of Type 1 and Type 2 diabetes, main risk factors contributing to DPN are smoking, obesity, hyperlipidemia, duration of diabetes, large total exposure to hyperglycemia, advanced age, elevated lipid levels, elevated blood pressure, kidney disease, cigarette smoking, overweight, increased height, and others.


The signs and symptoms of DPN include numbness, tingling, poor balance, pain: burning, electric shocks, stabbing, spontaneous pain at the affected site, hypersensitive to pain against nociceptive warmth stimulation, and others. 


Diagnosis 

This segment of the report covers the detailed diagnostic methods or tests for Diabetic Peripheral Neuropathy. 


Treatment 

It covers the details of conventional and current medical therapies available in the Diabetic Peripheral Neuropathy market for the treatment of the condition. It also provides Diabetic Peripheral Neuropathy treatment algorithms and guidelines in the United States, Europe, and Japan. 


Diabetic Peripheral Neuropathy Epidemiology  

The Diabetic Peripheral Neuropathy epidemiology division provide insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalence of Diabetic Peripheral Neuropathy in 7MM, Gender-Specific Prevalence of Diabetic Peripheral Neuropathy in 7MM, Total Diagnosed Prevalence of Painful Diabetic Peripheral Neuropathy in 7MM), scenario of Total Diagnosed Prevalence of Diabetic Peripheral Neuropathy in 7MM in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030.


DelveInsight’s estimations suggests the total prevalent cases of Diabetic Peripheral Neuropathy in the 7MM was found to be approximately 25,332,829 in 2017. Among 7MM, United States has the prevalent population of Diabetic Peripheral Neuropathy with about 12,522,483 cases in 2017. Among EU-5 countries, Germany has the highest prevalent cases with 3,904,730 cases, followed by Italy with 1,636,426 cases in 2017. However, Spain has the least number of diagnosed prevalent cases. All these cases are expected to increase by 2030.


Diabetic Peripheral Neuropathy Drug Chapters

This segment of the Diabetic Peripheral Neuropathy report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.


The management of pain remains the key aspect of symptom treatment for DPN. The current medications fall into categories, such as antidepressants, anticonvulsants, topical agents and opioids. Antidepressants are further divided into selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCA) group.


Treatments currently approved by both FDA and EMA for pain associated with DPN include—pregabalin, duloxetine, and extended-release tapentadol and capsaicin 8% patch. However, no treatments have been approved for the prevention or reversal of DPN.


Given the increasing population with diabetic peripheral neuropathy and the impact on their quality of life, an overview of effective treatments is warranted. Thus, it is important to establish the pathogenesis of pDPN and identify a therapeutic target. As microvascular complication is one of the factors to develop pDPN, patients may need a treatment targeting the improvement of blood circulation.


Various pharmaceutical companies are developing therapies such as VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) (WinSanTor, Inc.), Ricolinostat (Regenacy Pharmacuticals), NRD.E1 (Novaremed Ltd.), Cebranopadol (Grünenthal GmbH), GRC 17356 (Glenmark Pharmaceuticals), and others which are expected to enter the market by 2030 as effective therapies.


Diabetic Peripheral Neuropathy Market Outlook

The Diabetic Peripheral Neuropathy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.


According to DelveInsight, the market of Diabetic Peripheral Neuropathy in 7MM was found to be approximately USD 2,275.52 Million in 2017.


Diabetic Peripheral Neuropathy market size in the United States was maximum of the total market in 2017, followed by the EU5 and Japan respectively. 


Key Findings

This section includes a glimpse of the Diabetic Peripheral Neuropathy market in 7MM.


The United States Market Outlook

This section provides the total Diabetic Peripheral Neuropathy market size and market size by therapies in the United States.


EU-5 Countries: Market Outlook

The total Diabetic Peripheral Neuropathy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.


Japan Market Outlook 

The total Diabetic Peripheral Neuropathy market size and market size by therapies in Japan is also mentioned. 


Diabetic Peripheral Neuropathy Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

Various pharmaceutical companies are developing therapies such as VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) (WinSanTor, Inc.), Ricolinostat (Regenacy Pharmacuticals), NRD.E1 (Novaremed Ltd.), Cebranopadol (Grünenthal GmbH), GRC 17356 (Glenmark Pharmaceuticals), and others which are expected to enter the market by 2030 as effective therapies. 


Diabetic Peripheral Neuropathy Pipeline Development Activities 

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Diabetic Peripheral Neuropathy key players involved in developing targeted therapeutics. 


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Diabetic Peripheral Neuropathy emerging therapies.


Reimbursement Scenario in Diabetic Peripheral Neuropathy

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy. 


KOL- Views 

To keep up with current market trends, we take KOLs and SME's opinion working in Diabetic Peripheral Neuropathy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Diabetic Peripheral Neuropathy market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs. 


Competitive Intelligence Analysis 

We perform Competitive and Market Intelligence analysis of the Diabetic Peripheral Neuropathy Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.


Scope of the Report

  • The report covers the descriptive overview of Diabetic Peripheral Neuropathy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Diabetic Peripheral Neuropathy epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Diabetic Peripheral Neuropathy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Diabetic Peripheral Neuropathy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Diabetic Peripheral Neuropathy market


Report Highlights

  • In the coming years, Diabetic Peripheral Neuropathy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Peripheral Neuropathy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition       
  • Major players are involved in developing therapies for Diabetic Peripheral Neuropathy. Launch of emerging therapies will significantly impact the Diabetic Peripheral Neuropathy market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Diabetic Peripheral Neuropathy
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities


Diabetic Peripheral Neuropathy Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Diabetic Peripheral Neuropathy Pipeline Analysis
  • Diabetic Peripheral Neuropathy Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Diabetic Peripheral Neuropathy Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage 
  • Diabetic Peripheral Neuropathy Epidemiology Segmentation
  • Key Cross Competition 
  • Highly Analyzed Market
  • Drugs Uptake


Diabetic Peripheral Neuropathy Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers


Key Questions

Market Insights:

  • What was the Diabetic Peripheral Neuropathy market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Diabetic Peripheral Neuropathy total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Diabetic Peripheral Neuropathy market size during the forecast period (2017-2030)?
  • At what CAGR, the Diabetic Peripheral Neuropathy market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Diabetic Peripheral Neuropathy market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Diabetic Peripheral Neuropathy market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Diabetic Peripheral Neuropathy?
  • What is the historical Diabetic Peripheral Neuropathy patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Diabetic Peripheral Neuropathy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Diabetic Peripheral Neuropathy?
  • Out of all 7MM countries, which country would have the highest prevalent population of Diabetic Peripheral Neuropathy during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Diabetic Peripheral Neuropathy treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Diabetic Peripheral Neuropathy in the USA, Europe, and Japan?
  • What are the Diabetic Peripheral Neuropathy marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Diabetic Peripheral Neuropathy?
  • How many therapies are developed by each company for Diabetic Peripheral Neuropathy treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Diabetic Peripheral Neuropathy treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Diabetic Peripheral Neuropathy therapies? 
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies? 
  • What are the clinical studies going on for Diabetic Peripheral Neuropathy and their status?
  • What are the key designations that have been granted for the emerging therapies for Diabetic Peripheral Neuropathy?
  • What are the global historical and forecasted market of Diabetic Peripheral Neuropathy?


Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Diabetic Peripheral Neuropathy market
  • To understand the future market competition in the Diabetic Peripheral Neuropathy market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Diabetic Peripheral Neuropathy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Diabetic Peripheral Neuropathy market
  • To understand the future market competition in the Diabetic Peripheral Neuropathy market

1. Key Insights

2. Executive summary

3. Diabetic Peripheral Neuropathy (DPN): Market Overview at a Glance

3.1. Total Market Share (%) Distribution of DPN in 2017

3.2. Total Market Share (%) Distribution of DPN in 2030

4. Epidemiology and Market Methodology

5. Disease Background and Overview: Diabetic Peripheral Neuropathy (DPN)

5.1. Introduction

5.2. Classification of Diabetic Neuropathies

5.3. Signs and Symptoms

5.4. Risk Factors

5.5. Pathogenesis

5.6. Diagnosis

5.7. Recent developments in early diagnosis of DPN with POCDs

5.8. Differential Diagnosis

6. Epidemiology and Patient Population: Diabetic Peripheral Neuropathy (DPN)

6.1. Key Findings

6.2. Total Diagnosed Prevalent cases of Diabetic Peripheral Neuropathy (DPN) in 7MM

6.3. United States

6.3.1. Assumptions and Rationale

6.3.2. Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in the United States

6.3.3. Gender-Specific Cases of Diabetic Peripheral Neuropathy in the United States

6.3.4. Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in the United States

6.4. EU5

6.4.1. Assumptions and Rationale

6.5. Germany

6.5.1. Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Germany

6.5.2. Gender-Specific Cases of Diabetic Peripheral Neuropathy in Germany

6.5.3. Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Germany

6.6. France

6.6.1. Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in France

6.6.2. Gender-Specific Cases of Diabetic Peripheral Neuropathy in France

6.6.3. Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in France

6.7. Italy

6.7.1. Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Italy

6.7.2. Gender-Specific Cases of Diabetic Peripheral Neuropathy in Italy

6.7.3. Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Italy

6.8. Spain

6.8.1. Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Spain

6.8.2. Gender-Specific Cases of Diabetic Peripheral Neuropathy in Spain

6.8.3. Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Spain

6.9. United Kingdom (UK)

6.9.1. Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in the UK

6.9.2. Gender-Specific Cases of Diabetic Peripheral Neuropathy in the UK

6.9.3. Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in the UK

6.10. Japan

6.10.1. Assumptions and Rationale

6.10.2. Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Japan

6.10.3. Gender-Specific Cases of Diabetic Peripheral Neuropathy in Japan

6.10.4. Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Japan

7. Treatment and Management of DPN

7.1. Guidelines for the management of DPN

8. Unmet need

9. Marketed Drugs

9.1. Key cross competition

9.2. Qutenza: Grünenthal

9.2.1. Drug Description

9.2.2. Regulatory Milestones

9.2.3. Other developmental activities

9.2.4. Clinical Development

9.2.5. Safety and Efficacy

9.2.6. Product Profile

9.3. Tarlige: Daiichi Sankyo

9.3.1. Drug Description

9.3.2. Regulatory Milestones

9.3.3. Other developmental activities

9.3.4. Clinical Development

9.3.5. Safety and Efficacy

9.3.6. Product Profile

10. Emerging drugs

10.1. Key cross competition

10.2. VM202: Helixmith

10.2.1. Drug Description

10.2.2. Other developmental activities

10.2.3. Clinical Development

10.2.4. Clinical trials information

10.2.5. Safety and Efficacy

10.2.6. Product Profile

10.3. NYX-2925: Aptinyx

10.3.1. Drug Description

10.3.2. Other developmental activities

10.3.3. Clinical Development

10.3.4. Clinical trials information

10.3.5. Safety and Efficacy

10.3.6. Product Profile

10.4. WST-057: WinSanTor

10.4.1. Drug Description

10.4.2. Other developmental activities

10.4.3. Clinical Development

10.4.4. Clinical trials information

10.4.5. Product Profile

10.5. Ricolinostat: Regenacy Pharmaceuticals

10.5.1. Drug Description

10.5.2. Other developmental activities

10.5.3. Clinical Development

10.5.4. Clinical trials information

10.5.5. Safety and Efficacy

10.5.6. Product Profile

10.6. Cebranopadol: Grünenthal

10.6.1. Drug Description

10.6.2. Other developmental activities

10.6.3. Clinical Development

10.6.4. Clinical trials information

10.6.5. Safety and Efficacy

10.6.6. Product Profile

10.7. ISC 17536: Ichnos Science

10.7.1. Drug Description

10.7.2. Other developmental activities

10.7.3. Clinical Development

10.7.4. Clinical trials information

10.7.5. Safety and Efficacy

10.7.6. Product Profile

10.8. NRD135S.E1: Novaremed

10.8.1. Drug Description

10.8.2. Clinical Development

10.8.3. Clinical trials information

10.8.4. Safety and Efficacy

10.8.5. Product Profile

10.8.6. Other potential therapies

10.9. MEDI7352: AstraZeneca

10.9.1. Drug Description

10.9.2. Clinical Development

10.9.3. Clinical trials information

10.9.4. Product Profile

10.10. Trazodone/Gabapentin: Angelini

10.10.1. Drug Description

10.10.2. Clinical Development

10.10.3. Clinical trials information

10.10.4. Product Profile

11. Market Size: Diabetic Peripheral Neuropathy

11.1. Key Findings

11.2. Total Market Size of Painful Diabetic Peripheral Neuropathy in 7MM

11.3. Market Outlook: 7 MM

11.4. United States

11.4.1. Total Market size of Painful Diabetic Peripheral Neuropathy in the US

11.4.2. Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in the US

11.5. EU5

11.6. Germany

11.6.1. Total Market size of Painful Diabetic Peripheral Neuropathy in Germany

11.6.2. Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in Germany

11.7. France

11.7.1. Total Market size of Painful Diabetic Peripheral Neuropathy in France

11.7.1.1. Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in France

11.8. Italy

11.8.1. Total Market size of Painful Diabetic Peripheral Neuropathy in Italy

11.8.2. Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in Italy

11.9. Spain

11.9.1. Total Market size of Painful Diabetic Peripheral Neuropathy in Spain

11.9.2. Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in Spain

11.10. United Kingdom

11.10.1. Total Market size of Painful Diabetic Peripheral Neuropathy in the UK

11.10.2. Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in the UK

11.11. Japan

11.11.1. Total Market size of Painful Diabetic Peripheral Neuropathy in Japan

11.11.2. Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in Japan

12. Reimbursement policies

12.1. Access and Reimbursement Overview for Current and Future Therapies

12.2. Current Therapies

12.2.1. Capsaicin patch (Qutenza)

12.2.2. Mirogabalin besilate (Tarlige)

12.3. Future Therapies

12.3.1. Gene Therapy

12.3.2. Disease-modifying Therapy

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. KOL Views

17. Case Report

18. A Case Report of DPN

19. Bibliography

20. Appendix

21. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

Table 1: Classification for diabetic neuropathies

Table 2: Symptoms and signs of DPN

Table 3: The Toronto Diabetic Neuropathy Diagnostic definition

Table 4: A summary of the common tests used to assess neuropathy

Table 5: Screening and Diagnosis Recommendations by the American Diabetes Association

Table 6: Guidelines recommend the frequency and mode of assessment

Table 7: Clinical utility of devices used for the diagnosis of diabetic peripheral neuropathy

Table 8: Differential diagnosis of diabetic neuropathies

Table 9: Total Diagnosed Prevalent cases of DPN in 7MM (2017–2030)

Table 10: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in the US (2017–2030)

Table 11: Gender-Specific Cases of Diabetic Peripheral Neuropathy in the US (2017–2030)

Table 12: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in the US (2017–2030)

Table 13: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Germany (2017–2030)

Table 14: Gender-Specific Cases of Diabetic Peripheral Neuropathy in Germany (2017–2030)

Table 15: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Germany (2017–2030)

Table 16: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in France (2017–2030)

Table 17: Gender-Specific Cases of Diabetic Peripheral Neuropathy in France (2017–2030)

Table 18: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in France (2017–2030)

Table 19: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Italy (2017–2030)

Table 20: Gender-Specific Cases of Diabetic Peripheral Neuropathy in Italy (2017–2030)

Table 21: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Italy (2017–2030)

Table 22: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Spain (2017–2030)

Table 23: Gender-Specific Cases of Diabetic Peripheral Neuropathy in Spain (2017–2030)

Table 24: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Spain (2017–2030)

Table 25: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in the UK (2017–2030)

Table 26: Gender-Specific Cases of Diabetic Peripheral Neuropathy in the UK (2017–2030)

Table 27: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in the UK (2017–2030)

Table 28: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Japan (2017–2030)

Table 29: Gender-Specific Cases of Diabetic Peripheral Neuropathy in Japan (2017–2030)

Table 30: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Japan 2017–2030)

Table 31: Adjunctive therapies and preventive measures

Table 32: Pain management medications in DPN

Table 33: American Diabetes Association: Recommendation for the prevention of DSPN.

Table 34: American Diabetes Association: Recommendation for the Management of DSPN.

Table 35: American Diabetes Association: Recommendation for the Pain Management of DSPN

Table 36: Key cross of Marketed Drugs

Table 37: Qutenza, Clinical Trial Description, 2020

Table 38: Tarlige, Clinical Trial Description, 2020

Table 39: Key cross of emerging drugs- I

Table 40: Key cross of the emerging drugs –II

Table 41: VM202, Clinical Trial Description, 2020

Table 42: NYX-2925, Clinical Trial Description, 2020

Table 43: NYX-2925, Clinical Trial Description, 2020

Table 44: Ricolinostat, Clinical Trial Description, 2020

Table 45: Cebranopadol, Clinical Trial Description, 2020

Table 46: ISC 17536, Clinical Trial Description, 2020

Table 47: NRD135S.E1, Clinical Trial Description, 2020

Table 48: MEDI7352, Clinical Trial Description, 2020

Table 49: Trazodone/Gabapentin, Clinical Trial Description, 2020

Table 50: Total Market Size of Diabetic Peripheral Neuropathy in 7MM in USD Million (2017-2030)

Table 51: Total Market size of Painful Diabetic Peripheral Neuropathy in the US (2017–2030)

Table 52: Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in the US, in USD Million (2017-2030)

Table 53: Total Market size of Painful Diabetic Peripheral Neuropathy in Germany (2017–2030)

Table 54: Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in Germany, in USD Million (2017-2030)

Table 55: Total Market size of Painful Diabetic Peripheral Neuropathy in France (2017–2030)

Table 56: Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in France, in USD Million (2017-2030)

Table 57: Total Market size of Painful Diabetic Peripheral Neuropathy in Italy (2017–2030)

Table 58: Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in Italy , in USD Million (2017-2030)

Table 59: Total Market size of Painful Diabetic Peripheral Neuropathy in Spain (2017–2030)

Table 60: Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in Spain, in USD Million (2017-2030)

Table 61: Total Market size of Painful Diabetic Peripheral Neuropathy in the UK (2017–2030)

Table 62: Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in the UK , in USD Million (2017-2030)

Table 63: Total Market size of Painful Diabetic Peripheral Neuropathy in Japan (2017–2030)

Table 64: Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in Japan, in USD Million (2017-2030)




Figure 1: Epidemiology and Market Methodology

Figure 2: Classification of DPN

Figure 3: Clinical presentation of small and large fiber neuropathies

Figure 4: Signs and Symptoms of DPN

Figure 5: Risk factors of DPN

Figure 6: Risk factors of painful-DPN

Figure 7: Pathogenesis of diabetic neuropathy

Figure 8: Mechanisms of diabetic neuropathy

Figure 9: Total Diagnosed Prevalent cases of DPN in 7MM (2017–2030)

Figure 10: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in the US (2017–2030)

Figure 11: Gender-Specific Cases of Diabetic Peripheral Neuropathy in the US (2017–2030)

Figure 12: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in the US (2017–2030)

Figure 13: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Germany (2017–2030)

Figure 14: Gender-Specific Cases of Diabetic Peripheral Neuropathy in Germany (2017–2030)

Figure 15: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Germany (2017–2030)

Figure 16: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in France (2017–2030)

Figure 17: Gender-Specific Cases of Diabetic Peripheral Neuropathy in France (2017–2030)

Figure 18: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in France (2017–2030)

Figure 19: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Italy (2017–2030)

Figure 20: Gender-Specific Cases of Diabetic Peripheral Neuropathy in Italy (2017–2030)

Figure 21: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Italy (2017–2030)

Figure 22: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Spain (2017–2030)

Figure 23: Gender-Specific Cases of Diabetic Peripheral Neuropathy in Spain (2017–2030)

Figure 24: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Spain (2017–2030)

Figure 25: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in the UK (2017–2030)

Figure 26: Gender-Specific Cases of Diabetic Peripheral Neuropathy in the UK (2017–2030)

Figure 27: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in the UK (2017–2030)

Figure 28: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Japan (2017–2030)

Figure 29: Gender-Specific Cases of Diabetic Peripheral Neuropathy in Japan (2017–2030)

Figure 30: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Japan (2017–2030)

Figure 31: Treatment Algorithm of Diabetic Neuropathic Pain

Figure 32: Unmet Need of DPN

Figure 33: Total Market Size of Painful Diabetic Peripheral Neuropathy in 7MM in USD Million (2017-2030)

Figure 34: Market size of Painful Diabetic Peripheral Neuropathy in the US (2017–2030)

Figure 35: Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in the US, in USD Million (2017-2030)

Figure 36: Market size of Painful Diabetic Peripheral Neuropathy in Germany (2017–2030)

Figure 37: Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in Germany, in USD Million (2017-2030)

Figure 38: Market size of Painful Diabetic Peripheral Neuropathy in France (2017–2030)

Figure 39: Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in France, in USD Million (2017-2030)

Figure 40: Market size of Painful Diabetic Peripheral Neuropathy in Italy (2017–2030)

Figure 41: Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in Italy, in USD Million (2017-2030)

Figure 42: Market size of Painful Diabetic Peripheral Neuropathy in Spain (2017–2030)

Figure 43: Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in Spain, in USD Million (2017-2030)

Figure 44: Market size of Painful Diabetic Peripheral Neuropathy in the UK (2017–2030)

Figure 45: Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in the UK, in USD Million (2017-2030)

Figure 46:Market size of Painful Diabetic Peripheral Neuropathy in Japan (2017–2030)

Figure 47: Total Market Size of Painful Diabetic Peripheral Neuropathy by Therapies in Japan, in USD Million (2017-2030)

Figure 48: Market driver

Figure 49: Market Barrier

  • VM202 (Helixmith)
  • NYX-2925 (Aptinyx)
  • WST-057 (4% pirenzepine) (WinSanTor, Inc.)
  • Ricolinostat (Regenacy Pharmacuticals)
  • NRD.E1 (Novaremed Ltd.)
  • Cebranopadol (Grünenthal GmbH)
  • GRC 17356 (Glenmark Pharmaceuticals)
  • Tags:
  • Diabetic Peripheral Neuropathy mar...
  • Diabetic Peripheral Neuropathy ma...
  • Diabetic Peripheral Neuropathy m...
  • Diabetic Peripheral Neuropathy ma...
  • Diabetic Peripheral Neuropathy ma...
  • Diabetic Peripheral Neuropathy ma...
  • Diabetic Peripheral Neuropathy pi...
  • Diabetic Peripheral Neuropathy t...
  • Diabetic Peripheral Neuropathy d...
  • Diabetic Peripheral Neuropathy sa...
  • Diabetic Peripheral Neuropathy ma...
  • Diabetic Peripheral Neuropathy di...
  • Diabetic Peripheral Neuropathy ep...
  • Diabetic Peripheral Neuropathy

Forward to Friend

Need A Quote